No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
VRTX240705C482500
- 1.76
- 0.000.00%
15min DelayTrading Jun 28 12:58 ET
0.00High0.00Low
0.00Open1.76Pre Close0 Volume9 Open Interest482.50Strike Price0.00Turnover18.94%IV2.17%PremiumJul 5, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry1.76Extrinsic Value100Contract SizeAmericanOptions Type0.2259Delta0.0299Gamma394.96Leverage Ratio-0.3511Theta0.0133Rho89.22Eff Leverage0.1595Vega
Intraday
- 5D
- Daily
News
Insulet Tops S&P 500 Growth Chart for Q2 as It Gains Market Share in the Diabetes Space
Insider Sale at Vertex Pharmaceuticals Inc (VRTX): EVP and CMO Carmen Bozic Sells 2,280 Shares
Vertex Pharmaceuticals(VRTX.US) Officer Sells US$1.08 Million in Common Stock
Wells Fargo Updated Its Signature Picks, With Vertex Pharma and AvalonBay as Adds
This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Vertex Pharmaceuticals Initiated at Buy by Redburn Atlantic
Comments
The 13F filing for the hedge fund led by the late Jim Simons (RIP) just dropped and we got you covered
Here's a breakdown of the biggest moves:
🔴 SOLD (ranked by largest prev. portfolio %)
$Exxon Mobil(XOM.US$ : 0.70%
$Boeing(BA.US$ : 0.43%
$GE Aerospace(GE.US$ : 0.41%
$Alphabet-C(GOOG.US$ : 0.31%
$Netflix(NFLX.US$ : 0.31%
$Disney(DIS.US$ : 0.24%
🟢 NEW (ranked by portfolio %):
$Chevron(CVX.US$ : 0.52% ...
Here's a breakdown of the biggest moves:
🔴 SOLD (ranked by largest prev. portfolio %)
$Exxon Mobil(XOM.US$ : 0.70%
$Boeing(BA.US$ : 0.43%
$GE Aerospace(GE.US$ : 0.41%
$Alphabet-C(GOOG.US$ : 0.31%
$Netflix(NFLX.US$ : 0.31%
$Disney(DIS.US$ : 0.24%
🟢 NEW (ranked by portfolio %):
$Chevron(CVX.US$ : 0.52% ...
+1
18
Keep an eye on these M&As: 👀
Onconova Tx merger w/ Trawsfynydd Tx
$Aditxt(ADTX.US$ to acquire Appili Tx
TuHURA Biosciences merger w/ $Kintara Therapeutics(KTRA.US$
$Johnson & Johnson(JNJ.US$ to acquire $ShockWave Medical(SWAV.US$
$Vertex Pharmaceuticals(VRTX.US$ to acquire $Alpine Immune(ALPN.US$
$Century Therapeutics(IPSC.US$ to acquire Clade Tx
$Eliem Therapeutics(ELYM.US$ to acquire Tenet Med.
$Incyte(INCY.US$ to acquire Escient Pharm.
ONO Pharm to acquire $Deciphera Pharmaceuticals(DCPH.US$
...
Onconova Tx merger w/ Trawsfynydd Tx
$Aditxt(ADTX.US$ to acquire Appili Tx
TuHURA Biosciences merger w/ $Kintara Therapeutics(KTRA.US$
$Johnson & Johnson(JNJ.US$ to acquire $ShockWave Medical(SWAV.US$
$Vertex Pharmaceuticals(VRTX.US$ to acquire $Alpine Immune(ALPN.US$
$Century Therapeutics(IPSC.US$ to acquire Clade Tx
$Eliem Therapeutics(ELYM.US$ to acquire Tenet Med.
$Incyte(INCY.US$ to acquire Escient Pharm.
ONO Pharm to acquire $Deciphera Pharmaceuticals(DCPH.US$
...
7
No megadeals in biotech so far this yr, but on track for record amount >$1 bil deals,
2 biggest deals this yr:
$Vertex Pharmaceuticals(VRTX.US$ paid $4.9 bil for $Alpine Immune(ALPN.US$
$Gilead Sciences(GILD.US$ paid $4.3 bil for $CBAY
Bolt-on deals likely to continue to be the dominant story in 2024, which means we could also see more of this trend...
Last yr 84% of M&A deal dollars were for Biotechs w/ Phase 3 & Marketed assets,
In the first four months of 2024 56% of M&A deal dollar went towards P...
2 biggest deals this yr:
$Vertex Pharmaceuticals(VRTX.US$ paid $4.9 bil for $Alpine Immune(ALPN.US$
$Gilead Sciences(GILD.US$ paid $4.3 bil for $CBAY
Bolt-on deals likely to continue to be the dominant story in 2024, which means we could also see more of this trend...
Last yr 84% of M&A deal dollars were for Biotechs w/ Phase 3 & Marketed assets,
In the first four months of 2024 56% of M&A deal dollar went towards P...
6
$Vertex Pharmaceuticals(VRTX.US$ reported on May 6 first quarter adjusted earnings and revenue that beat analysts' estimates.
The company reported adjusted earnings of $4.76 a share on product revenue of $2.69 billion for the three months that ended March 31. Analysts estimates compiled by LSEG called for adjusted earnings of $4.06 per share and product revenue of $2.58 billion, according to Reuters.
The company kept its pr...
The company reported adjusted earnings of $4.76 a share on product revenue of $2.69 billion for the three months that ended March 31. Analysts estimates compiled by LSEG called for adjusted earnings of $4.06 per share and product revenue of $2.58 billion, according to Reuters.
The company kept its pr...
4
Read more
淡定的惠特莫爾 : Last time you asked me to buy sofi? A lot of falls
淡定的惠特莫爾 :
EZ_moneyOP 淡定的惠特莫爾: Sofi all you have to do is buy under 7 and hold. you don't lose unless you sell for a lost. hold until above 7 easy
淡定的惠特莫爾 EZ_moneyOP: Oh! Thank you
EZ_moneyOP 淡定的惠特莫爾:
View more comments...